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If in doubt [Preoperative evaluation of non–small cell lung
cancer] . . .
Michael A. Maddaus, MD
If in doubt, give the patient the benefit of the doubt.” Dr Robert Ginsbergtaught me this while I trained with him in the early 1990s at MemorialSloan-Kettering Cancer Center. Since that moment, I have adhered to thisprinciple, with frequent significant benefit to my patients.Noninvasive radiologic preoperative staging of non–small cell lung can-cer (NSCLC) has dramatically changed over the past decade. High-resolu-
tion spiral computed tomography (CT) can now delineate nearly all enlarged hilar
and mediastinal lymph nodes and can detect other lung nodules as small as 1.0 mm.
Positron emission tomography (PET) scanning now provides a whole-body image
search for metastases. Whether CT or PET is used, a problem arises when a result
is equivocal or uncertain. With PET scanning, the answer to a negative result may
be easy—operate. A positive result, however, may open a Pandora’s box of clinical
interpretations, ranging from obviously positive (eg, a definite hot spot on a rib), to
a faint smudge of positivity (with the surgeon asking the radiologist, “Do you think
there is anything really there?”), to errors of interpretation (eg, kidney, renal
collecting ducts, bladder, liver). This frequent haze of uncertainty is a regular event
with radiologic results.
The article by Buccheri and Ferrigno1 attempts to improve on the accuracy of
preoperative radiologic evaluation with a simple serum test for two tumor markers:
tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). TPA, a
member of the cytokeratin family, consists of proteolytic fragments of the cytoker-
atins 8, 18, and 19. Because TPA is made up of cytoskeleton fragments, elevated
levels tend to represent increased cell division and turnover of a tumor. Hypothet-
ically, larger, more advanced tumors may have higher cell division and death rates,
with correspondingly higher levels of serum TPA. CEA, a cell-surface glycoprotein
of the immunoglobulin gene superfamily, is normally expressed in secretory tissues.
CEA may be important for intercellular adhesion and attachment; through those
functions it is thought to be potentially involved in tumor cell metastasis.
In the study by Buccheri and Ferrigno, 124 consecutive patients—whose NSCLC
had been staged primarily by chest, abdominal, and brain CT (with no PET and only
rare mediastinoscopy)—underwent surgical resection. Preoperative serum TPA and
CEA levels were correlated with surgical resectability, defined as “pathologic
postoperative documentation of stage Ia through IIb disease.” The independent
accuracy of CT (chest, abdominal, brain) in predicting surgical resectability was
77%; that of TPA levels, 65%; and that of CEA levels, 69%. Low levels of TPA
(90 U/L) and CEA (10 ng/mL) increased the accuracy of CT to 83% and 85%,
respectively. Conversely, elevated levels of TPA and CEA increased the accuracy of
CT to 89% and 100%.
Buccheri and Ferrigno defined a cutoff for resectability at the IIb to IIIa point.
This cutoff represents relatively advanced disease, most of which would now be
detected with PET scanning and mediastinoscopy. Although serum measurements
of various tumor markers such as TPA and CEA may incrementally improve staging
accuracy, particularly with more advanced disease, a gray zone of uncertainty still
remains that can be dispelled only by tissue staging.
The search for a more accurate means of preoperative staging is entering a new
and exciting phase, ushered in by advances in molecular biology. With PCR
techniques, occult micrometastatic tumor cells can now be detected in histologically
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normal lymph nodes, bone marrow, or blood. In addition,
with quantitative PCR, the number of occult micrometa-
static tumor cells in a given tissue sample can now be
quantitated. Two current trials, the Cancer and Leukemia
Group B 9761 and the American College of Surgeons
Oncology Group, are now in the process of evaluating the
detection of occult micrometastases in patients with
NSCLC. The results of these two trials will shed light on the
predictive value of such molecular techniques. The ability
to preoperatively determine a patient’s micrometastatic tu-
mor burden would fundamentally alter preoperative evalu-
ation and treatment planning.
About 50% of patients with lung cancer now die within
5 years after curative-intent resection. Clearly, our current
ability to detect unfavorable tumor biology and dissemi-
nated malignant disease is limited. Until molecular-based
techniques are routinely available, which will occur, the
onus is still on the thoracic surgeon to give the patient the
benefit of the doubt.
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